Compare Gilead Sciences, Inc. (GILD) vs Global E Online Ltd (GLBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Global E Online Ltd — how do they compare? Gilead Sciences, Inc. trades at $134.61 (market cap $163.51B), while Global E Online Ltd trades at $38.43 (market cap $6.55B). The key difference: Gilead Sciences, Inc. is far larger — about 25× Global E Online Ltd's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals.
| GILD | GLBE | |
|---|---|---|
Market Cap | $163.51B | $6.55B |
Sector | Health | Technology |
52-Week High | $155.80 | $41.59 |
52-Week Low | $108.22 | $27.54 |
Enterprise Value | $178.05B | $6.02B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
GLBE trades at $38.70, down 0.13% on the day, with a strong bullish technical signal from moving averages. The company reported Q1 2026 revenue growth of 33% year-over-year and raised full-year 2026 guidance, while maintaining a high P/E ratio of 58.18. Recent acquisition of Passport aims to enhance logistics capabilities, supporting future growth in cross-border e-commerce.
Outlook remains positive with 100% analyst buy ratings and a consensus price target of $38.00, though high valuation and recent insider sales present risks. Earnings momentum and strategic expansions provide upside potential, but investors should monitor competitive pressures and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →
